U.K. Next-Generation Sequencing (NGS) Services Market (2017-2022)
The U.K. Next-Generation Sequencing (NGS) Services Market was valued at $92 Million in 2017 and projected to reach to $226.4 Million by 2022, representing a compound annual growth rate of 19.7%. The U.K.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
U.K. Next-Generation Sequencing (NGS) Services Market Trends and Insights
- Next-Generation Sequencing (NGS) Services Market was valued at $92.0 million in 2017 and is projected to expand to $226.4 million by 2022, representing a compound annual growth rate (CAGR) of 19.7%.
- The U.K.
- market is experiencing robust expansion driven by increasing adoption of genomic testing in clinical diagnostics, personalized medicine initiatives, and growing investment in precision healthcare infrastructure.
- The U.K.
- benefits from a well-established healthcare system and strong research institutions that are accelerating NGS service deployment across oncology, rare disease diagnosis, and pharmacogenomics applications. The U.K.
- NGS Services Market growth trajectory reflects rising demand for cost-effective sequencing solutions and expanding clinical applications.
- The U.K.
- healthcare sector's emphasis on precision medicine and early disease detection is propelling service adoption among hospitals, diagnostic laboratories, and research centers.
- Between 2017 and 2022, the U.K.
- market is anticipated to more than double in value, positioning the country as a significant growth hub within the European NGS services landscape..
Key Market Statistics
- CAGR (2017-2022) 19.7% CAGR
- Market Size, 2017 ~USD 92 Million
- Forecast, 2022 ~USD 226.4 Million
- Country U.K.
U.K. Next-Generation Sequencing (NGS) Services Market Overview
Market Valuation Growth :
The U.K. NGS Services Market grew from $92.0 million in 2017 to $226.4 million by 2022, demonstrating strong market expansion and increasing healthcare investment in genomic technologies.
Clinical Diagnostics Adoption :
U.K. healthcare providers are rapidly integrating NGS into clinical diagnostics, driven by NHS initiatives and the shift toward precision medicine in oncology, rare disease diagnosis, and genetic screening programs.
Personalized Medicine Initiatives :
The U.K. government's commitment to genomic medicine, including the 100,000 Genomes Project, has accelerated adoption of NGS services across NHS trusts and private diagnostic laboratories.
Research & Investment Momentum :
Increased funding from U.K. research institutions, biotech companies, and healthcare providers is driving innovation in NGS service delivery, data analysis, and interpretation capabilities.
U.K. Next-Generation Sequencing (NGS) Services Market Dynamics
- NGS Services Market is positioned for sustained growth through 2022 and beyond, supported by the NHS's genomic medicine strategy and increasing prevalence of cancer and genetic disorders requiring advanced diagnostic solutions.
- The 19.7% CAGR reflects growing confidence in NGS technology reliability and cost-effectiveness among U.K.
- healthcare institutions. Key drivers include expanding clinical applications, integration of NGS into routine diagnostics, and rising demand for personalized treatment approaches.
- U.K.
- laboratories are investing in automation and bioinformatics infrastructure to handle increased testing volumes, while regulatory frameworks continue to evolve to support clinical implementation and data governance standards..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Key Takeaways
- The U.K. NGS Services Market is projected to grow from $92.0M (2017) to $226.4M (2022) at a 19.7% CAGR.
- The U.K. healthcare system's focus on precision medicine and genomic diagnostics is driving rapid market expansion.
- The U.K. market is expected to more than double in value over the five-year forecast period.
- The U.K. benefits from strong research infrastructure and clinical adoption of NGS across multiple therapeutic areas.
Next-Generation Sequencing (NGS) Services Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2017 |
| Fastest Growing Segment | AGRICULTURE & ANIMAL RESEARCH (Application) |
| Forecast Period | 2017–2022 |
| Growth Rate | CAGR of 21% from 2017 to 2022 |
| Largest Segment | DIAGNOSTICS (Application) |
| Market Size Base Year (Billions) | ~USD 1.06 (2017) |
| Revenue Forecast (Billions) | ~USD 2.748 (2022) |
| Segments Covered | Type, Application, End User, Technology |
U.K. Next-Generation Sequencing (NGS) Services Market Report Segmentation
4 segment dimensions are covered across the global market.
By Type
- Chip-Seq
- De Novo Sequencing
- Exome Sequencing
- Methyl-Seq
- Other Ngs Services
- Other Services
- Rna-Seq
- Targeted Sequencing/Custom Gene Panels
- Targeted Sequencing/Gene Panels
- Whole-Genome Sequencing
By Application
- Agriculture & Animal Research
- Biomarker Discovery
- Diagnostics
- Drug Discovery
- Infectious Diseases
- Oncology
- Other Applications
- Other Applications*
- Other Diagnostic Applications
- Rare Genetic Disorders
- Reproductive Health
By End User
- Academic & Government
- Academic & Government Institutes And Research Centers
- Hospitals & Clinics
- Other End Users
- Other End Users*
- Pharmaceutical & Biotechnology Companies
By Technology
- Ion Semiconductor Sequencing
- Nanopore Sequencing
- Sequencing By Synthesis
- Single-Molecule Real-Time Sequencing
Target Audience
- NHS Trust Executives : Hospital and trust leaders need U.K. market data to justify NGS infrastructure investments, understand adoption benchmarks across NHS regions, and align genomic medicine strategies with national initiatives.
- Diagnostic Laboratory Managers : Laboratory directors require market insights to assess competitive positioning, identify growth opportunities in clinical NGS services, and plan capacity expansion within the U.K. healthcare system.
- Biotech & Medtech Companies : U.K.-focused biotech firms and international companies entering the British market need localized market data to develop go-to-market strategies, identify partnership opportunities, and forecast revenue potential.
- Healthcare Investors & Consultants : Investment firms and management consultants advising healthcare clients require U.K.-specific NGS market analysis to evaluate investment opportunities, assess portfolio companies, and guide strategic decisions.
- Genomic Medicine Researchers : Academic and research institutions need market data to understand commercialization opportunities, secure funding, and align research initiatives with U.K. healthcare priorities and industry trends.
Key Companies in the U.K. Next-Generation Sequencing (NGS) Services Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ILLUMINA, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| PERKINELMER, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| EUROFINS SCIENTIFIC SE | Luxembourg | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| MACROGEN, INC. | South Korea | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| QIAGEN N.V. | Netherlands | Public Company | Targeted sequencing services (panels, amplicon, gene panels),RNA-Seq services,Exome and de novo sequencing services, |
| DNA LINK, INC. | South Korea | Public Company | Whole genome & De Novo sequencing services,Whole exome & targeted sequencing services,Transcriptome & single-cell RNA sequencing, |
| TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.) | Japan | ||
| NOVOGENE CORPORATION | China | Public Company | Whole genome and targeted sequencing services (incl. human/animal/plant/microbial WGS and targeted panels),Transcriptomics and single-cell sequencing (mRNA, lncRNA, small RNA, single-cell, spatial),De novo, metagenomics, and microbiome sequencing, |
| PERSONALIS, INC. | United States | Public Company | Oncology MRD and monitoring (NeXT Personal, NeXT Personal Dx),Comprehensive tumor profiling (ImmunoID NeXT, NeXT Dx),Population and research sequencing (WES/WGS services), |
ILLUMINA, INC.
Illumina, Inc. is a public company founded in 1998 and headquartered in the United States with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies.
PERKINELMER, INC.
PerkinElmer, Inc. is a public company founded in 1937 and based in the United States with 11,000 employees. The company provides diagnostic and research solutions across life sciences and environmental testing.
EUROFINS SCIENTIFIC SE
Eurofins Scientific SE is a public company founded in 1987 and headquartered in Luxembourg with 65,694 employees. The company operates a network of laboratories providing testing and analytical services across multiple industries.
MACROGEN, INC.
Macrogen, Inc. is a public company founded in 2000 and based in South Korea with 293 employees. The company provides genomic research services including DNA sequencing and analysis.
QIAGEN N.V.
QIAGEN N.V. is a public company founded in 1984 and headquartered in the Netherlands with 5,500 employees. The company develops and manufactures molecular diagnostics and life sciences tools.
DNA LINK, INC.
DNA Link, Inc. is a public company founded in 2000 and based in South Korea with 84 employees. The company offers genomic analysis and genetic testing services.
TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.)
Takara Bio Inc. is a company based in Japan and operates as part of Takara Holding Company Inc. The company specializes in biotechnology and life sciences research products.
NOVOGENE CORPORATION
Novogene Corporation is a public company founded in 2011 and based in China with 2,225 employees. The company provides genomic sequencing and bioinformatics analysis services.
PERSONALIS, INC.
Personalis, Inc. is a public company founded in 2011 and based in the United States with 260 employees. The company develops genomic testing and analysis solutions for precision medicine.
Reasons to Buy this Report
- U.K.-Specific Market Sizing : Obtain precise valuation data for the U.K. NGS Services Market with historical (2017) and forecast (2022) figures, enabling accurate budget allocation and market entry strategies tailored to the British healthcare landscape.
- NHS Integration Insights : Understand how NHS initiatives and the 100,000 Genomes Project are reshaping NGS service demand, adoption rates, and reimbursement models specific to U.K. public and private healthcare providers.
- Competitive Landscape Analysis : Identify key U.K. NGS service providers, laboratory capabilities, and market consolidation trends to benchmark your organization's positioning and identify partnership or acquisition opportunities.
- Clinical Application Trends : Gain detailed insights into which clinical specialties (oncology, rare diseases, prenatal screening) are driving NGS adoption in the U.K., informing service development and marketing strategies.
- Regulatory & Reimbursement Framework : Access analysis of U.K. regulatory requirements, NICE guidelines, and NHS reimbursement pathways for NGS services, critical for compliance and revenue forecasting in the British market.
Frequently asked questions
What is the current size of the U.K. NGS Services Market?
The U.K. NGS Services Market was valued at $92.0 million in 2017 and is forecast to reach $226.4 million by 2022.
What is the expected growth rate for the U.K. NGS Services Market?
The U.K. NGS Services Market is expected to grow at a compound annual growth rate (CAGR) of 19.7% from 2017 to 2022.
What factors are driving growth in the U.K. NGS Services Market?
The U.K. market is driven by increasing adoption of genomic testing in clinical diagnostics, personalized medicine initiatives, growing investment in precision healthcare infrastructure, and expanding clinical applications in oncology and rare disease diagnosis.
Which healthcare segments are adopting NGS services in the U.K.?
The U.K. NGS services are being adopted across hospitals, diagnostic laboratories, research centers, and clinical settings for oncology, rare disease diagnosis, and pharmacogenomics applications.
How does the U.K. NGS Services Market compare to other European markets?
The U.K. NGS Services Market is positioned as a significant growth hub within Europe, with strong research institutions and a well-established healthcare system supporting rapid market expansion and clinical adoption.
RESEARCH METHODOLOGY
Get the Full Next-Generation Sequencing (NGS) Services Market Report
Full forecast, segment splits, and company analysis for all Next-Generation Sequencing (NGS) Services Market.
- Canada Next-Generation Sequencing (NGS) Services Market
- Germany Next-Generation Sequencing (NGS) Services Market
- France Next-Generation Sequencing (NGS) Services Market
- China Next-Generation Sequencing (NGS) Services Market
- Japan Next-Generation Sequencing (NGS) Services Market
- India Next-Generation Sequencing (NGS) Services Market
- U.S. Next-Generation Sequencing (NGS) Services Market
- Roe Next-Generation Sequencing (NGS) Services Market
- Roapac Next-Generation Sequencing (NGS) Services Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
